Mirae Asset Global Etfs Holdings Ltd. Nektar Therapeutics Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $41.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Nektar Therapeutics stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 97,954 shares of NKTR stock, worth $91,097. This represents 0.0% of its overall portfolio holdings.
Number of Shares
97,954Holding current value
$91,097% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NKTR
# of Institutions
145Shares Held
139MCall Options Held
32.6KPut Options Held
14.1K-
Deep Track Capital, LP Greenwich, CT15.9MShares$14.8 Million0.76% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$14.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$12.2 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA9.4MShares$8.74 Million0.22% of portfolio
-
Samlyn Capital, LLC New York, NY9.2MShares$8.56 Million0.19% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $174M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...